Efficacy and safety of topical ganciclovir in the management of cytomegalovirus (CMV)-related anterior uveitis

摘要

The aim of this study was to evaluate the efficacy and safety of topical ganciclovir 0.15?% gel in the management of patients with cytomegalovirus (CMV) anterior uveitis. This was a retrospective cohort study of the disease course of 31 patients (33 eyes) with aqueous polymerase chain reaction (PCR) positive for CMV. Data from a total of 160 episodes of anterior uveitis flare for 20?years, dating from December 1992 to December 2012, was collected. All patients were treated with concomitant topical anti-inflammatory medication. The disease course of each eye was analysed before and after the use of topical ganciclovir 0.15?%. The mean age at initial presentation of anterior uveitis was 57.5?±?12.6?years. Twenty-eight (90.3?%) patients were Chinese. Patients on topical ganciclovir gel had a statistically significant fewer episodes of uveitis flare per person year (median ?0.88 episodes/person years, p?=?0.029). The time-to-quiescence was not significantly affected by topical ganciclovir use (median ?1.25?days, p?=?0.610). In the survival analysis using the Cox regression model, the use of topical ganciclovir was associated with a lower risk of recurrence, but this was not statistically significant (hazard ratio?=?0.857, 95?% CI 0.543–1.36, p?=?0.511). The overall median time-to-recurrence was 290?days (95?% CI 113 to 274?days) and 164?days (125 to 404?days) (p?=?0.492), with and without topical ganciclovir, respectively. Topical ganciclovir may be beneficial in reducing the frequency of recurrence in patients with CMV anterior uveitis, but it was not statistically associated with prolonging the time-to-recurrence. The time-to-quiescence was also not significantly affected by topical ganciclovir. Prospective studies with a larger number of patients would be required to verify our findings.